Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
24 05 2019
Historique:
received: 10 01 2019
accepted: 10 04 2019
revised: 05 04 2019
entrez: 26 5 2019
pubmed: 28 5 2019
medline: 7 2 2020
Statut: epublish

Résumé

Mild-cognitive impairment (MCI) occurs in up to one-fifth of individuals over the age of 65, with approximately a third of MCI individuals converting to dementia in later life. There is a growing necessity for early identification for those at risk of dementia as pathological processes begin decades before onset of symptoms. A cohort of 122 individuals diagnosed with MCI and followed up for a 36-month period for conversion to late-onset Alzheimer's disease (LOAD) were genotyped on the NeuroChip array along with pathologically confirmed cases of LOAD and cognitively normal controls. Polygenic risk scores (PRS) for each individual were generated using PRSice-2, derived from summary statistics produced from the International Genomics of Alzheimer's Disease Project (IGAP) genome-wide association study. Predictability models for LOAD were developed incorporating the PRS with APOE SNPs (rs7412 and rs429358), age and gender. This model was subsequently applied to the MCI cohort to determine whether it could be used to predict conversion from MCI to LOAD. The PRS model for LOAD using area under the precision-recall curve (AUPRC) calculated a predictability for LOAD of 82.5%. When applied to the MCI cohort predictability for conversion from MCI to LOAD was 61.0%. Increases in average PRS scores across diagnosis group were observed with one-way ANOVA suggesting significant differences in PRS between the groups (p < 0.0001). This analysis suggests that the PRS model for LOAD can be used to identify individuals with MCI at risk of conversion to LOAD.

Identifiants

pubmed: 31127079
doi: 10.1038/s41398-019-0485-7
pii: 10.1038/s41398-019-0485-7
pmc: PMC6534556
doi:

Substances chimiques

Apolipoprotein E4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

154

Subventions

Organisme : NIA NIH HHS
ID : U24 AG021886
Pays : United States
Organisme : Medical Research Council
ID : MR/L501542/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : U01 AG016976
Pays : United States
Organisme : Medical Research Council
ID : G1100540
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG033193
Pays : United States
Organisme : Medical Research Council
ID : MR/J004758/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701075
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901254
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K01417X/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : N01AG12100
Pays : United States
Organisme : Medical Research Council
ID : G1001253
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : U01 AG032984
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL105756
Pays : United States
Organisme : Parkinson's UK
ID : G-1307
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Références

J Neural Transm (Vienna). 2013 May;120(5):807-12
pubmed: 23180304
J Alzheimers Dis. 2018;66(4):1635-1644
pubmed: 30452415
Alzheimers Dement. 2015 Dec;11(12):1452-1460
pubmed: 26086184
Neurology. 2016 Aug 2;87(5):481-8
pubmed: 27385740
Am J Psychiatry. 2018 Jun 1;175(6):555-563
pubmed: 29495896
N Engl J Med. 2013 Jan 10;368(2):107-16
pubmed: 23150908
Neurology. 2017 Mar 21;88(12):1180-1186
pubmed: 28213371
PLoS One. 2015 Mar 04;10(3):e0118432
pubmed: 25738806
Neurobiol Aging. 2017 Jan;49:214.e7-214.e11
pubmed: 27595457
Nat Genet. 2013 Dec;45(12):1452-8
pubmed: 24162737
BMC Neurol. 2015 Mar 28;15:47
pubmed: 25880661
Ann Neurol. 2017 Sep;82(3):484-488
pubmed: 28940650
Bioinformatics. 2015 May 1;31(9):1466-8
pubmed: 25550326
Ann Neurol. 2017 Aug;82(2):311-314
pubmed: 28727176
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Biol Psychiatry. 2013 Mar 1;73(5):429-34
pubmed: 22592056
J Alzheimers Dis. 2015;43(2):565-73
pubmed: 25096612
Expert Rev Mol Med. 2016 May 30;18:e11
pubmed: 27237222
J Alzheimers Dis. 2016 Jun 18;53(3):921-32
pubmed: 27340842
Mol Psychiatry. 2019 Mar;24(3):421-430
pubmed: 29487403
Neurobiol Aging. 2018 Feb;62:244.e1-244.e8
pubmed: 29103623
Neurobiol Aging. 2017 Sep;57:247.e9-247.e13
pubmed: 28602509
Nat Genet. 2017 Sep;49(9):1373-1384
pubmed: 28714976
J Alzheimers Dis. 2018;64(2):355-362
pubmed: 29914034
Neurobiol Aging. 2016 Apr;40:68-77
pubmed: 26973105
eNeuro. 2016 Jul 15;3(3):
pubmed: 27482534
Oncotarget. 2015 Nov 10;6(35):36955-64
pubmed: 26543236
N Engl J Med. 2013 Jan 10;368(2):117-27
pubmed: 23150934
Acta Psychiatr Scand. 2009 Apr;119(4):252-65
pubmed: 19236314
Cereb Cortex. 2012 Nov;22(11):2653-61
pubmed: 22169231
Clin Interv Aging. 2017 Nov 13;12:1941-1949
pubmed: 29180857
PLoS Med. 2017 Mar 21;14(3):e1002258
pubmed: 28323831
Brain. 2015 Dec;138(Pt 12):3673-84
pubmed: 26490334
Alzheimers Dement. 2015 Nov;11(11):1277-85
pubmed: 25916564
Arch Gen Psychiatry. 2006 Feb;63(2):168-74
pubmed: 16461860
J Alzheimers Dis. 2017;56(1):25-36
pubmed: 27911318
Curr Neurol Neurosci Rep. 2013 Oct;13(10):381
pubmed: 23954969
Alzheimer Dis Assoc Disord. 2016 Jul-Sep;30(3):195-202
pubmed: 26756387
Nat Genet. 2009 Oct;41(10):1094-9
pubmed: 19734903
Nat Rev Genet. 2018 Sep;19(9):581-590
pubmed: 29789686
Neurobiol Aging. 2015 Jan;36(1):60-7
pubmed: 25189118
Bioinformatics. 2015 Aug 1;31(15):2595-7
pubmed: 25810428

Auteurs

Sultan Chaudhury (S)

Human Genetics Group, University of Nottingham, Nottingham, UK.

Keeley J Brookes (KJ)

Human Genetics Group, University of Nottingham, Nottingham, UK. keeley.brookes@nottingham.ac.uk.

Tulsi Patel (T)

Human Genetics Group, University of Nottingham, Nottingham, UK.

Abigail Fallows (A)

Human Genetics Group, University of Nottingham, Nottingham, UK.

Tamar Guetta-Baranes (T)

Human Genetics Group, University of Nottingham, Nottingham, UK.

James C Turton (JC)

Human Genetics Group, University of Nottingham, Nottingham, UK.

Rita Guerreiro (R)

UK Dementia Research Institute at University College London and ION Department of Neurodegenerative Disease, London, UK.

Jose Bras (J)

UK Dementia Research Institute at University College London and ION Department of Neurodegenerative Disease, London, UK.

John Hardy (J)

UK Dementia Research Institute at University College London and ION Department of Neurodegenerative Disease, London, UK.

Paul T Francis (PT)

Brains for Dementia Research Resource, Wolfson CARD, King's College London, London, UK.

Rebecca Croucher (R)

Faculty of Medicine, University of Southampton, Southampton, UK.

Clive Holmes (C)

Faculty of Medicine, University of Southampton, Southampton, UK.

Kevin Morgan (K)

Human Genetics Group, University of Nottingham, Nottingham, UK.

A J Thomas (AJ)

Institute of Neuroscience Biomedical Research Building Campus for Ageing and Vitality Newcastle University, Newcastle upon Tyne, NE4 5PL, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH